Mr. Fangzhou Zhang has extensive experience in corporate m88 bonus mergers & acquisitions, foreign investment, m88 bonus private equity/venture capital. He specializes in investment, mergers m88 bonus acquisitions, licensing transactions, m88 bonus regulatory compliance in the life sciences m88 bonus healthcare industry. Mr. Zhang has represented numerous domestic m88 bonus international clients in transaction structuring, legal due diligence, drafting m88 bonus negotiation of transaction documents, closing matters m88 bonus post-closing matters. He has experience in sectors including pharmaceuticals (biologics, chemical drugs, m88 bonus traditional Chinese medicine), medical devices, in vitro diagnostics, healthcare services, wind m88 bonus photovoltaic power generation, m88 bonus lithium mining. His past clients include Temasek, PAG, Siemens Healthineers, BD, Roche, Grifols, BioNTech, Gilead, Waters, SQM, Sembcorp Energy, Tencent, Sino Biopharmaceutical, Genor Biopharma, Yangtze River Pharmaceutical, Sinopharm Group, Shanghai Pharmaceuticals, Tasly, BioRay, Innovent Biologics, Zelgen Biopharmaceuticals, Chia Tai Tianqing, m88 bonus Yiling Pharmaceutical.

Mr. Zhang was recognized as a "Recommended Lawyer" in the field of Life Sciences m88 bonus Healthcare by The Legal 500 Asia Pacific. The Temasek-led Series C financing of Abogen, in which he participated, was selected as one of China Business Law Journal’s Deals of the Year.